SCHEMBL24319574

SCHEMBL24319574

CCc1c([N+](=O)[O-])ccc(F)c1C(=O)Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PDK1 Q15118 1/20 0.38
ALDH1A1 P00352 8/20 0.37
MAPT P10636 3/20 0.37
FBP1 P09467 2/20 0.37
POLB P06746 1/20 0.37
HIF1A Q16665 1/20 0.37
LMNA P02545 3/20 0.35
RECQL P46063 1/20 0.35
VCAM1 P19320 1/20 0.35
CASP6 P55212 1/20 0.35
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 2/20 0.34
GAA P10253 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24320056 0.86 TDP1 (0.44) ATMTDP1ALDH1A1MAPTFBP1
SCHEMBL18985184 0.80 TDP1 (0.44) ATMTDP1ALDH1A1MAPTPOLB
SCHEMBL288357 0.79 TDP1 (0.43) ATMTDP1ALDH1A1MAPTPOLB
SCHEMBL12987642 0.78 TDP1 (0.47) ATMTDP1ALDH1A1MAPTPOLB
SCHEMBL30635283 0.75 MAPT (0.44) ALDH1A1MAPTPOLBLMNAHTT
SCHEMBL28674613 0.74 TDP1 (0.41) ATMTDP1ALDH1A1MAPTPOLB
SCHEMBL26693768 0.73 TDP1 (0.41) ATMTDP1ALDH1A1MAPTPOLB
SCHEMBL793112 0.72 TDP1 (0.49) ATMTDP1ALDH1A1MAPTHIF1A
SCHEMBL29158045 0.72 ALDH1A1 (0.42) ATMTDP1PDK1ALDH1A1MAPT
SCHEMBL11749334 0.72 TSHR (0.49) TDP1ALDH1A1MAPTFBP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2025-07-24 US disclosed
US-12180193-B2 Accelerating fibrosarcoma protein degrading compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-12-31 US disclosed
CN-117062814-A Compounds that rapidly accelerate fibrosarcoma protein degradation and related methods of use 阿维纳斯运营公司 2023-11-14 CN disclosed
EP-4204418-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2023-07-05 EP disclosed
US-20230081501-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-16 US disclosed
WO-2022047145-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-03-03 WO disclosed
WO-2022047145-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230081501-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE CRBN, RBX1, ARAF ATM 1531/4885TDP1 1696/4885PDK1 2656/4885
US-12180193-B2 Accelerating fibrosarcoma protein degrading compounds and associated methods of use CRBN, RBX1, ARAF ATM 1575/4885TDP1 1620/4885PDK1 2764/4885
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE CRBN, RBX1, ARAF ATM 1531/4885TDP1 1696/4885PDK1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.